Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment
Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment
Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It
 affects 150 million people annually. Treatment of patients with UTI entails a high
 consumption of antibiotics and large social and health costs. With this protocol, we want to
 elucidate alternative treatment methods for especially recurrent urinary tract infection.
 Bacteria have internal competitiveness (bacterial interference) and it is known that the
 non-pathogenic E.coli can outcompete the pathogenic E.coli in laboratory studies.

 We intend to strengthen the clinical evidence that it can be used as patient treatment
 through a clinical, placebo-controlled, double-blind trial at Odense University Hospital.
Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It
 affects 150 million people annually. Treatment of patients with UTI entails a high
 consumption of antibiotics and large social and health costs. With this protocol, we want to
 elucidate alternative treatment methods for especially recurrent urinary tract infection.
 Bacteria have internal competitiveness (bacterial interference) and it is known that the
 non-pathogenic E.coli can outcompete the pathogenic E.coli in laboratory studies.

 We intend to strengthen the clinical evidence that it can be used as patient treatment
 through a clinical, placebo-controlled, double-blind trial at Odense University Hospital.

 Claim to be investigated:

 -  The non-pathogenic bacterial strain (ABU) E.coli can overcome the most common pathogenic
 E.coli (UPEC) in humans.

 -  ABU can be used for preventive treatment in patients with recurrent urinary tract
 infections.

 Clinical effect of preventive treatment (prophylactic treatment) with the non-pathogenic
 bacterial strain (ABU) in a selected group of patients with recurrent cystitis: A clinical,
 placebo-controlled, double-blind safety study.
Inclusion Criteria:

 -  Diagnosed with recurrent cystitis including 2 times of rUTI within the last 6 months
 or 3 times in the last 12 months, where at least 2 cultures show the same bacteria.

 -  Normal investigation for lower urinary tract diseases (LUTD) including voiding diary,
 symptom scores, flexible cystoscopy, voiding diagram and test for residual urine.

 -  Failed previously treatments.

 -  Patients with native bladder with both spontaneous voiding, the need for clean
 intermittent catheter (CIC) or indwelling catheter.

 -  Patients with neurogenic and non-neurogenic bladder dysfunction.

 -  Patients with urostomy, kidney transplantation or another complicated genesis.

 -  Written consent.

 Exclusion Criteria:

 -  Malignancy in the urinary tract, kidney-, ureteral- or bladder stones, age < 18 years,
 pregnancy, breastfeeding. Patients in ongoing orally antibiotic treatment. Not able to
 speak or understand Danish.